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Bronchial asthma is now increasingly recognized in the elderly and is associated with significant morbidity and 
mortality. The aims of this study were two-fold: first, to assess the prevalence and, second, to evaluate diagnostic 
awareness, therapeutic management and patient perception of bronchial asthma among elderly patients in the 
community. 
From the age-sex register of an urban general practice in NE England, 2004 patients aged >65 years were eligible 
for inclusion. Response to an initial screening questionnaire on respiratory symptomatology was 68% (n= 1362). Of 
these, 869 patients had respiratory symptoms: 390 voluntarily agreed to be evaluated further including assessment 
of airway physiology. In this group 369/390 had obstructive spirometry and, of these, 95 patients fulfilled clinical and 
physiological criteria of bronchial asthma. Prevalence of asthma within this age cohort was minimally and rather 
crudely assigned at 4.5% (9512004). 
Among the 95 patients so-defined patients with asthma [age 70 & 8 years (mean f SD), FEV, =0.96 f 0.4 1, 33 
male, 75 life-long non-smokers], subjective awareness, perception and attribution of pulmonary symptoms were 
poor. Further, despite tangible evidence of reversible and significant airflow limitation, only 21 were receiving 
inhaled glucocorticoid therapy (median daily dose 400 pug). 
Asthma in the elderly remains poorly perceived, poorly recognized and suboptimally treated. These findings are 
particularly apposite in the light of current epidemiological trends in asthma mortality and morbidity in elderly age 
cohorts. 
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Introduction 
Asthma is a common disease with an overall prevalence of 
up to 7-8% of the general population (1). Further, there 
is a steady increase in the prevalence of asthma from 
adolescence to old age (1). A universally accepted 
definition, however, remains an elusive goal. Estimates of 
prevalence differ greatly from country to country and even 
within the same country because of the variable criteria 
employed to establish the diagnosis. The problem is 
compounded in older age groups because of overlap of 
diagnostic labels and poor patient perception of symptoms. 
Since Ford (2) and Lee and Stretton (3) emphasized the 
prevalence of the condition in elderly patients, a number of 
epidemiological studies have confirmed that asthma is 
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common in the elderly (4-13). Of particular concern are 
statistics regarding mortality from asthma which appears to 
be increasing throughout the world, especially among 
persons aged 55 years and older (14). The increase in deaths 
is most marked in the older age groups. In 1990, 50% of all 
recorded asthma deaths in England and Wales occurred in 
the 65-84 year age group, and a further 10% occurred in 
those aged over 85 years (15). There has also been concern 
that asthma is underdiagnosed (3,16-19) and hence not 
adequately treated in the elderly. To address some of these 
issues, we have conducted a community survey to assess 
prevalence, diagnostic awareness, therapeutic management 
and patient perception of bronchial asthma among elderly 
subjects in an urban general practice in the north-east of 
England. 
Methods 
All subjects who participated in the study gave written 
and informed consent which was approved by the 
Sunderland local research ethics committee. The study was 
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of cross-sectional design. The age-sex register of an urban 
group general practice in the north east of England during 
the period October 1992-May 1993 was used to identify 
subjects over the age of 65. Patients so identified were sent 
a previously validated screening questionnaire (20) that 
enquired about five respiratory symptoms: (1) cough on 
winter mornings, (2) sputum expectoration on winter 
mornings, (3) wheezing or whistling in the chest, (4) short- 
ness of breath on washing and dressing and (5) distance 
walked on the level before becoming short of breath. Up to 
two reminders were sent. Patients who responded positively 
to at least one symptom and who were voluntarily agree- 
able to further evaluation were visited at home by a 
trained nurse and completed the Medical Research Council 
(MRC) respiratory questionnaire (21) under supervision 
and underwent spirometric assessments. 
Spirometric assessments were performed in a sitting 
position with a Portable Micro Medical Printer Spirometer 
(Micro Medical Ltd, Rochester, Kent, U.K.), which was 
calibrated daily before use. Airway parameters measured 
were (a) forced expiratory volume in 1 s (FEV,), (b) forced 
vital capacity (FVC) and (c) peak expiratory flow rate 
(PEFR). Patients were required to perform three satisfac- 
tory spirometric techniques within 5% of each other by 
FVC: the best of these three manoeuvres for each of the 
airway parameters was recorded by the trained nurse and 
print-outs of the spirograms were verified by a clinician 
(D.C.) to confirm adequate technique. No repeatability 
measurements of these assessments were undertaken 
subsequently in any of the patients. 
Bronchodilator reversibility of airflow obstruction was 
assessed 15 min after the inhalation of 2OOpg of salbutamol 
from a metered-dose inhaler using a large-volume spacer 
device. Height and arm span were measured to the nearest 
centimetre and predicted values for lung function were 
calculated from regression equations derived from the 
report of the working party of the European Community 
for Coal and Steel (22). A diagnosis of asthma was assigned 
on the basis of clinical criteria: (i) daytime symptoms of 
episodic cough and wheeze or (ii) similar nocturnal 
symptoms suggestive of heightened airway reactivity 
supplemented with one of two objective physiologic criteria 
of airflow reversibility; (iii) 2 15% increase in FEV, or (iv) 
an absolute increase in FEV, or FVC 2 200 ml following 
salbutamol inhalation. 
STATISTICAL ANALYSIS 
Normally distributed data was assessed parametrically by 
the paired t test. Correlation between variables was assessed 
using Pearson’s test. A P value of ~0.05 was considered 
significant. Data are expressed as mean * standard 
deviation (SD) unless otherwise stated. 
Results 
From the age-sex general practice register, 2004 patients 
were eligible for inclusion into the study. A total of 1362 
adequately completed screening questionnaires were 
TABLE l(a). Spirometric measurements of those patients 




( f SD> (% predicted) 
FEV, 0.96 f 0.4 1 53 
FVC 1.93 f 0.7 1 82 
FEV,/FVC 50.6% f 13.5% 
PEFR 120 f 67 1 min - ’ 35 




(n = 33) (n = 62) Significance 
FEV, (% predicted) 45.6 57.0 PCO.02 
FVC (% predicted) 73.4 86.8 PCO.02 
FEVJFVC (%) 46.8 52.6 n.s. 
PEFR (% predicted) 34.0 35.2 n.s. 
returned (response rate 68%). Of these, 869 patients 
responded positively to at least one of the screening 
questions and 390 of these patients agreed voluntarily to be 
visited at home for further assessment including physiologic 
evaluation. Of these 390 patients, 369 had obstructive 
spirometry, defined as an FEV,/FVC ratio <70%, and, of 
these, 95 patients satisfied our clinical and physiological 
criteria for bronchial asthma. 
Of the 95 patients defined as having asthma, 33 were male 
and 75 were life-long non-smokers. The mean age of the 
group was 70 f 8 years. Spirometric characteristics of these 
patients are summarized in Table l(a) with gender differ- 
ences illustrated in Table l(b). Male asthmatic patients had 
significantly lower FEV, and FVC [P<O.O2, Table l(b)]. 
SYMPTOMS 
The majority of patients (84/95) experienced wheeze and/or 
chest tightness on moderate exertion. Thirteen patients 
were severely incapacitated and house bound because of 
dyspnoea. Twenty-seven patients had significant nocturnal 
morbidity With symptoms of wheeze, cough and chest 
tightness. One patient reported a worsening of asthma 
symptoms related to aspirin ingestion. 
PATIENT PERCEPTION AND AWARENESS OF 
THEIR PULMONARY SYMPTOMS 
Only seven patients were aware they had a clinical diagnosis 
of bronchial asthma. The majority (84/95) believed that 
asthma was not responsible for their breathlessness, and 
24 perceived that there was nothing wrong with their chest. 
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FIG. 1. Scatter plot showing daily dose of inhaled gluco- 
corticoid @g) versus magnitude of airflow limitation 
(expressed as percentage of FEV, predicted) in 21 
patients. A modest, but statistically significant, negative 
correlation was observed (r= - 0.59); PcO.01; n=21). 
Additional patient attributions for their perceived 
breathlessness included cigarette smoking, ‘bronchitis’, 
dust-related pulmonary morbidity and possible cardiac 
pathology. 
THERAPEUTIC MANAGEMENT 
Of the 95 patients defined as suffering from asthma, 43 were 
not receiving any form of anti-asthma medication. By 
contrast, of the 52 patients who were receiving treatment, 
39 were managed solely with inhaled therapy, three with 
oral therapy alone and ten with a combination of inhaled 
and oral medication. The majority of inhaled therapy was 
delivered from pressurized metered-dose inhalers. 
Of those patients receiving medication, only 21/52 (40%) 
were being administered chronic disease modifying treat- 
ment in the form of inhaled corticosteroids (GCS). The 
median daily dose was 400 pug (range 200-2000 pg): only six 
patients were receiving daily doses of inhaled GCS 
2 800 pg. A modest, but statistically significant, negative 
correlation between daily received dose of inhaled gluco- 
corticoid and magnitude of airflow limitation (expressed as 
percentage predicted FEV,) was observed (Y= - 0.59, 
P<O.Ol) and is represented in Fig. 1. 
In 88 of the 95 designated asthmatic patients, their 
asthma therapy was classified according to current 
therapeutic strategies as advocated in the British Thoracic 
Society Guidelines for the treatment of chronic persistant 
asthma (23). Seven patients could not be so classified. These 
data in comparison with airway physiology are shown 
in Table 2. The majority of patients (67/88, 76%) were 
receiving either no treatment or merely medication for 
symptomatic relief. For the group as a whole, only 24% 
(21188) were receiving inhaled GCS. No patient was 
receiving systemic corticosteroid therapy. 
TABLE 2. Airway physiology compared with therapeutic 
management as designated by British Thoracic Society 
strategies (as published in 1993) for the management of 
chronic persistent asthma (n=88; seven patients could not 
be allocated to a therapeutic step due to lack of sufficient 
data), 
Treatment Number of 
strategy patients 
Mean FEV, & SD 
(% predicted) 
No treatment 43 56.5 f 23.7 
Step 1 24 53.8 f 23.0 
Step 2 17 41.6 f 16.9 
Step 3 2 40.0 f 10.0 
Step 4 2 35.5 f 8.2 
Step 5 0 
Therapeutic treatment strategies are as follows: step 1, 
occasional use of relief bronchodilators; step 2, regular 
inhaled anti-inflammatory agents (low-dose inhaled GCS, 
up to 8OOpg daily); step 3, high-dose inhaled GCS (up to 
2000,~~g daily); step 4, (high-dose inhaled GCS and regular 
bronchodilators; step 5, addition of regular systemic steroid 
medication. 
Discussion 
In this community-based, cross-sectional study conducted 
among elderly patients in an urban general practice in the 
U.K., we have shown that pulmonary morbidity due to 
respiratory symptoms is common and that physiologically 
demonstrable reversible airflow limitation is poorly 
perceived, poorly recognized and suboptimally treated. 
These data are particularly apposite in the light of epi- 
demiological trends in asthma morbidity and mortality in 
the elderly and with the further impending revision of 
therapeutic strategies for the treatment of chronic persistent 
asthma by the British Thoracic Society. 
We are nevertheless aware of a number of potential 
criticisms of this study. Perhaps the most significant is that 
the study as it stands is not a true epidemiological survey. 
First, the data were acquired from only one urban group 
general practice, not several, and thus may not have been 
representative of a wider catchment area. Second, while the 
initial response rate to the postal questionnaire was 
68%, non-responders (642/2004, 32%) despite up to two 
reminders, were untraced. Further, of the 869 who initially 
responded positively to at least one screening question, only 
390 agreed to further domiciliary physiological assessment 
although this was done on a voluntary basis. It is thus 
clearly arguable that these 390 patients (representing only 
19.5% of the potential original study population) and the 
subsequent 369 documented to have obstructive spirometry 
constituted an unrepresentative group. Indeed, a similar 
argument may be applied to the final 95 patients who 
ultimately fulfilled our clinical and physiologic criteria of 
asthma. The data thus have to be interpreted accordingly as 
the potential study population shrank at progressive stages 
of evaluation. 
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Our assignment of obstructive spirometry was an FEV,/ 
FVC ratio of ~70%. Other studies in comparable age 
cohorts have utilized lower ratios (24), suggesting that our 
assessment of the prevalence of airflow limitation may 
have been significantly overestimated. Our definition of a 
diagnosis of asthma neverthless was applied vigorously and 
uniformly and was assigned on both clinical and physio- 
logical criteria. The latter included two definitions of air- 
flow reversibility based on both percentage and absolute 
spirometric improvement following salbutamol inhalation. 
Further, we are confident of the technical validity of our 
spirometric assessments, although, given the cross-sectional 
nature of the study, repeatability of these parameters at 
different time points was not evaluated. 
While the dose of &-agonist (200 ,ug salbutamol) used to 
assess airway reversibility could be considered modest and 
indeed may not have produced maximal bronchodilation, 
this potential attenuation of therapeutic effect may have 
been, in part, offset by our definition of airflow limitation 
based on a higher baseline FEVJFVC ratio. Even so, 
the patients nevertheless so identified (n=95) did have, by 
definition, reversible airflow limitation. Although partially 
reversible chronic obstructive pulmonary disease could not 
be unequivocally excluded, this seems unlikely given that 75 
of these 95 patients were life-long non-smokers. 
Epidemiological evidence has suggested that it is difficult 
to assign precise figures to the prevalence and incidence of 
asthma in the elderly in the general population because 
there is no universally accepted definition of the condition. 
However, large population studies from the United States 
and Europe, using self-reported symptom questionnaires 
and objective assessments of lung function, have provided 
good estimates. Despite the employment of a detailed 
respiratory questionnaire and objective assessments of lung 
function, our estimation of prevalence of asthma among the 
elderly in this study was limited by methodological difficul- 
ties as the initial study population diminished with progres- 
sive selection, and this was perhaps compounded by our 
definition of airflow limitation. Our very crude estimation 
of a prevalence of 4.5% (9512004) of asthma in the elderly 
from the data of this study has thus to be interpreted 
accordingly. 
A further limitation of surveys employing questionnaires 
is that underestimation of prevalence of asthma in the 
elderly may be related to impaired subjective awareness of 
symptomatology (19,25). Indeed, this was illustrated in our 
population sample, in which only seven patients were aware 
that they had a clinical diagnosis of the condition. It is 
noteworthy that of the 95 patients so identified as having 
asthma, 24 (25%) believed they had no pulmonary pathol- 
ogy, presumably as result of evolving strategies to perceive 
and cope with their morbidity. 
Current smoking, age and non-specific airway respon- 
siveness have been shown to be independently related to the 
risk of developing wheezing symptoms in older men (26). In 
the currently reported study, airway reactivity was not 
assessed, and only 20/95 defined asthma patients had a 
history of tobacco smoking, of whom only two were current 
cigarette smokers at the time of assessment. Further, earlier 
studies of asthma in subjects over the age of 70 years in the 
general population have shown men to have more severe 
forms of the disease (9). While this observation was 
confirmed in our study [Table l(b)], the explanation is 
unclear but may relate in part to a number of compounding 
factors including previous occupational environment, 
previous smoking habit, disease chronicity and suboptimal 
therapeutic management. 
Perhaps the most significant observation of this study 
was the magnitude of therapeutic undertreatment of the 
so-defined patients with asthma. This may well have been a 
consequence of these patients’ poor expectation of health, 
with resignation to chronic pulmonary morbidity as an 
inevitable sequel de ~OVO to the aging process. Allied to this, 
although we have no objective data to support this, their 
utilization of primary health care resources may have been 
poor despite ongoing significant pulmonary symptoms. An 
alternative interpretation would be that at times of interface 
with health care professionals, pulmonary symptoms were 
not appropriately recognized, addressed clinically or objec- 
tively assessed physiologically. Further, although we cannot 
comment directly on the co-existence of extrapulmonary 
pathology, this may, at least in part, have influenced both 
health care professionals and patients in their expectation 
of disease amelioration. While therapeutic compliance was 
not an outcome evaluated in this study, excessive morbidity 
in those patients prescribed therapy for asthma may have 
been attributed to non-compliance. Non-compliance in 
asthma, as with other chronic clinical conditions, is well 
documented, although previous studies have suggested that 
this is less of a problem in elderly, as opposed to younger, 
patients with the condition (5). 
The elucidation and characterization of asthma as a 
chronic inflammatory condition of the human airway 
characterized by heightened airway responsiveness to a 
variety of bronchoprovocative stimuli has led to clarifica- 
tion of therapeutic strategies. Numerous published con- 
sensus international guidelines relating to the diagnosis 
and management of asthma emphasize the promotion of 
bronchodilatation and, most importantly, attenuation of 
the airway inflammatory response. Indeed, the current 
British guidelines on asthma management (23) advocate the 
early and progressive use of inhaled GCS therapy for all but 
the mildest of asthmatic patients. Notwithstanding the 
plethora of evidence-based data relating to the disease- 
modifying effects of these drugs in bronchial asthma (27), a 
particular aspect of significant therapeutic concern in this 
study was the observation of the low rate of prescribed 
inhaled GCS therapy. Despite tangible objective evidence 
of reversible airflow limitation in 95 patients, approxi- 
mately 75% were not receiving inhaled GCS. Furthermore, 
within the minority of patients who were receiving inhaled 
GCS, daily therapeutic requirements were modest. The tacit 
assumption is made in view of the physiological evidence 
that all 95 patients so identified with variable airway calibre 
were potentially steroid responsive, however heterogenous 
the magnitude of that potential response. We are unable to 
comment from our data, however, given the design of the 
study, on whether inhaled or indeed systemic GCS therapy 
had previously been administered to those patients not 
receiving this therapy at the time of assessment, and the 
documented clinical and physiological response, if any, to 
such an intervention. Nevertheless, the absence or perceived 
suboptimal treatment of these patients with inhaled GCS 
has significant pulmonary prognostic implications: it is 
exceedingly unlikely that a younger cohort of asthmatic 
patients with comparable reversible airflow limitation 
would have been so undertreated. 
In conclusion, this study has clearly identified a lack of 
recognition and awareness of the possibility of the diagnosis 
of bronchial asthma in elderly patients in the community. 
Lack of diagnostic awareness was allied to poor patient 
perception of respiratory symptoms and suboptimal thera- 
peutic management. The major implications of this study 
are that, irrespective of age, accurate clinical evaluation 
coupled with objective assessments of airway physiology 
should be undertaken in all patients reporting respiratory 
symptoms and potential disease-modifying inhaled and/or 
systemic therapy appropriately assessed. This is applicable 
to all clinicians in both primary and secondary health care 
provision, and particularly to those who evaluate elderly 
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